Eli Lilly To Build $6.5 Billion Houston Plant For Obesity Pill Amid Surging GLP-1 Demand

Benzinga

Eli Lilly will invest $6.5B in a new Houston plant as part of a $27B U.S. expansion. The facility will produce obesity and diabetes drugs, creating thousands of jobs and boosting domestic pharmaceutical output.

Transcript

00:00It's Benzinga, bringing Wall Street to Main Street.

00:02Eli Lilly said Tuesday it will spend $6.5 billion to build a manufacturing facility in Houston,

00:07Texas to produce small molecule drugs, according to CNBC. Production is part of a $27 billion

00:12domestic expansion announced earlier this year, following $23 billion invested since 2020.

00:17The company plans to reveal two more U.S. sites this year and expects production across all four

00:22facilities within five years. Eli Lilly aims to scale output of its experimental obesity pill,

00:27or for Gliberon, seen as a crucial addition to the booming GLP-1 obesity and diabetes market.

00:33Houston Plant will also support drugs in cardiometabolic health, oncology, immunology,

00:38and neuroscience, creating 615 permanent jobs and 4,000...

00:43For all things money, visit Benzinga.com.

Category

Transcript

Be the first to comment

Recommended